| 主权项 |
1. A compound having the formula:or a pharmaceutically acceptable salt thereof, wherein:
A is 5 or 6-membered monocyclic heteroarylene, which is optionally substituted with up to 4 groups, which can be the same or different, and are selected from halo, hydroxy, C1-C6 alkyl, —O—(C1-C6 alkyl), C1-C6 haloalkyl, —S(O)2—(C1-C6 alkyl), 5 or 6-membered monocyclic heterocycloalkyl, 9 or 10-membered bicyclic heteroaryl, —N(R5)2, —NO2, —O—(C1-C6 alkylene)-C(O)OR5, and —CN, wherein said 5 or 6-membered monocyclic heteroarylene group can optionally have one of its ring carbon atoms derivatized as a ring carbonyl group; B is 8 to 10-membered bicyclic heteroaryl having from 1 to 4 ring heteroatoms, each independently selected from N, O and S, wherein said 8 to 10-membered bicyclic heteroaryl group is optionally substituted with up to 4 Rc groups, which can be the same or different, and are selected from:
a) halogen,b) OHc) C1-C6 alkyl,d) O(C1-C6 alkyl),e) CN,f) (CH2)0-3-ArB, wherein each ArB is an independently selected aromatic ring system selected from the group consisting of:
i) 5- or 6-membered monocyclic rings with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from the group consisting of N, O or S, andii) 8-, 9- or 10-membered bicyclic rings with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from the group consisting of N, O or S,g) (CH2)0-3NRdC(O)Re,h) (CH2)0-3NRdSO2Re,i) (CH2)0-3C(O)NRdRe,j) (CH2)0-3SO2Re,k) —OSO2(C1-C6 alkyl);l) —C(O)OR5; andm) —(C1-C6 alkylene)-O—(C1-C6 alkylene)-Si(R8)3, wherein the following Rc groups: c) C1-C6 alkyl, d) O(C1-C6 alkyl), and f) (CH2)0-3-ArB, can each be optionally substituted with up to 4 substituents Rf; each Rd is independently selected from the group consisting of hydrogen and C1-6 alkyl; each Re is independently selected from the group consisting of hydrogen, C1-6alkyl, OC1-6alkyl and 5- or 6-membered monocyclic rings with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from the group consisting of N, O or S, wherein each ReC1-6alkyl, OC1-6alkyl and 5- or 6-membered monocyclic rings is substituted by 0, 1, 2, 3 or 4 substituents independently selected from the group consisting of C1-C6 alkyl, O(C1-C6 alkyl), halogen and OH; each Rf is independently selected from the group consisting of:
a) halogen,b) C1-C6 alkyl,c) O(C1-C6 alkyl),d) CN,e) N(Rq)2,f) OH,g) C(O)H,h) NHC(O)Rs,i) NHS(O)2Rs,j) C(O)NHRq,k) C(O)ORq,l) OS(O)2(C1-C6 alkyl),m) (CH2)0-3-ArC, wherein each ArC is an independently selected aromatic ring system selected from the group consisting of:
i) 5- or 6-membered monocyclic rings with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from the group consisting of N, O or S, andii) 8-, 9- or 10-membered bicyclic rings with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from the group consisting of N, O or S, wherein the following Rf groups: b) C1-C6 alkyl, c) O(C1-C6 alkyl), and m) (CH2)0-3-ArC can be optionally substituted with up to 4 substituents Rg; each Rg is independently selected from the group consisting of halogen, —OH, —N(Rq)2, —CN, C1-6alkyl, —O—(C1-C6 alkyl), —CF3 and —C(O)OH; each Rq is independently selected from the group consisting of H and C1-6alkyl; each Rs is independently selected from the group consisting of C1-6alkyl, heterocyclyl and C6-10aryl, wherein said heterocyclyl group can be optionally substituted on a ring nitrogen or ring carbon atom with a —C(O)O—(C1-C6 alkyl) group; R4 is H, —N(R6)SO2R7 or each occurrence of R5 is independently H or C1-C6 alkyl; R6 is C1-C6 alkyl or C1-C6 haloalkyl; R7 is independently C1-C6 alkyl; and each occurrence of R8 is independently C1-C6 alkyl. |
